Clinical Research Directory

Inclusion Criteria: * Histologically and/or cytologically proven locally advanced (Stage II or III) or metastatic (Stage IV) pancreatic, adenocarcinoma * Inoperable pancreatic cancer due to at least one of the following: a) unresectability, b) metastatic disease, c) medically unfit for surgery * ECOG performance status ≤ 2 * Measurable lesion per RECIST (version 1.1) criteria * Maximum lesion of 4cm in the longest diameter (including primary tumor and regional lymph nodes) * ≥ 18 years of age * Estimated life expectancy of at least 12 weeks * Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test * Subjects are willing to sign an informed consent Exclusion Criteria: * Prior chemotherapy does not exclude the patient * Prior abdominal radiation therapy * Concomitant chemotherapy or immunotherapy * Borderline resectable pancreatic cancer and medically fit for surgery * Connective tissue disease (scleroderma, lupus) * Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.) * Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids * Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT * High probability of protocol non-compliance (in opinion of investigator) * Patients not willing to sign an informed consent form * Women who are pregnant or lactating